Long‐term safety and efficacy of emicizumab for up to 5.8 years and patients’ perceptions of symptoms and daily life: A phase 1/2 study in patients with severe haemophilia A

INTRODUCTION: Safety and efficacy results of the phase 1 study and phase 1/2 extension study of the bispecific antibody emicizumab in patients with severe haemophilia A with or without factor VIII inhibitors for up to 2.8 years were reported previously. AIM: To evaluate further longer‐term data incl...

Descripción completa

Detalles Bibliográficos
Autores principales: Shima, Midori, Nagao, Azusa, Taki, Masashi, Matsushita, Tadashi, Oshida, Koichi, Amano, Kagehiro, Nagami, Sayaka, Okada, Norihiro, Maisawa, Shingo, Nogami, Keiji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894561/
https://www.ncbi.nlm.nih.gov/pubmed/33236410
http://dx.doi.org/10.1111/hae.14205

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7894561/
https://www.ncbi.nlm.nih.gov/pubmed/33236410
http://dx.doi.org/10.1111/hae.14205

Ejemplares similares